102. Rubinstein-Taybi syndrome Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 3 / Drugs : 5 - (DrugBank : 1) / Drug target genes : 7 - Drug target pathways : 17
Rubinstein-Taybi syndrome and other diseases between which drug repositioning might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Drug repositionability
| ID | Diseases (Sorted by drug repositionability) |
|---|---|
| 102 | Rubinstein-Taybi syndrome |
| 13 | Multiple sclerosis/Neuromyelitis optica |
| 6 | Parkinson disease |
| 34 | Neurofibromatosis |
| 65 | Primary immunodeficiency |
| 85 | Idiopathic interstitial pneumonia |
| 89 | Lymphangioleiomyomatosis |
| 127 | Frontotemporal lobar degeneration |
| 222 | Primary nephrotic syndrome |
| 256 | Muscle glycogenosis |
| 331 | Idiopathic multicentric castleman disease |
| 26 | HTLV-1-associated myelopathy |
| 90 | Retinitis pigmentosa |
| 5 | Progressive supranuclear palsy |
| 233 | Wolfram syndrome |
| 3 | Spinal muscular atrophy |
| 2 | Amyotrophic lateral sclerosis |
| 149 | Hemiconvulsion hemiplegia epilepsy syndrome |
| 215 | Tetralogy of Fallot |
| 58 | Hypertrophic cardiomyopathy |
| 86 | Pulmonary arterial hypertension |